Shareholders’ proposal for election of Board of Directors
November 14, 2024
The shareholders of CombiGene AB (publ) (“CombiGene” or the “Company”) have previously been given notice to
The shareholders of CombiGene AB (publ) (“CombiGene” or the “Company”) have previously been given notice to
July – September 2024• Net sales: TSEK 0 (992).• Other operating revenues: TSEK 793 (173).• Profit
The shareholders of CombiGene AB (publ) reg. no. 556403-3818, (the “Company”) are hereby given notice to
The Board of Directors of CombiGene AB (publ) (“CombiGene” or the “Company”) has received proposals for
CombiGene AB (publ) (“CombiGene”, “the Company”) announces today that it intends to sharpen its strategic focus
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces preliminary results from completed analyzes of the latest
April – June 2024Net sales: TSEK 0 (1,788).Other operating revenues: TSEK 416 (1,413).Profit from financial items:
CombiGene AB (publ) (“CombiGene”, “the Company”) today announces that the Company has entered into a license
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that the company intends to change Certified Adviser
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will